A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.

Enveda’s pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas was host to the Bladder Cancer Course and the session Metastatic Urothelial Cancer. Dr. Vadim S. Koshkin ...

A recent study in Nature Materials introduces an inhalable nanozyme treatment for viral pneumonia, showing promising results ...

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.The research ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Prof. Daugaard will deliver a podium presentation highlighting Rakovina Therapeutics’ research and the Company’s product development pipeline, followed by examples of various model systems used by the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...